Discover and read the best of Twitter Threads about #AHA22
Most recents (14)
1) Welcome to a new #accredited #tweetorial on #hypertrophic #cardiomyopathy #HCM. Our expert author is Ahmad Masri MD @MasriAhmadMD of @OHSUCardio where he leads the Hypertrophic Cardiomyopathy Ctr. See a previous program from him, on #Fabry disease, at cardiometabolic-ce.com/cardiorenal-fa…. 
2a) This program is intended for #healthcare providers and is supported by an educational grant from Bristol-Myers Squibb. Statement of accreditation and faculty disclosures at cardiometabolic-ce.com/disclosures/. FOLLOW US for the most timely expert education in #cardiometabolic care!
2b) #Physicians #Nurses #PhysicianAssociates #NursePractitioners #Pharmacists earn a full 1⃣ hour of 🆓CE/#CME credit from following this 🧵. For educational purposes, Twitter still works!! 😁
Top 7 clinical trials in #AHA22 (#AHA2022) on #heartfailure #CardioTwitter
Slides from the brief I'll give today to our team @rambam_hospital
@EricTopol @drjohnm @PSJhund @HeartFailureFrm
You better be strong than sorry - Ultrarapid up-titration vs. Usual care
@AlexMebazaa
Slides from the brief I'll give today to our team @rambam_hospital
@EricTopol @drjohnm @PSJhund @HeartFailureFrm
You better be strong than sorry - Ultrarapid up-titration vs. Usual care
@AlexMebazaa
Inter-atrial shunting by Occlutech.
Tailoring shunt size (8/10mm) to LVEDP.
Importantly, identifying the super-responders (high LVEDP, E/e', BNP)
Another solid support for RV safety, though no control yet.
Tailoring shunt size (8/10mm) to LVEDP.
Importantly, identifying the super-responders (high LVEDP, E/e', BNP)
Another solid support for RV safety, though no control yet.
In my opinion, the biggest news from #AHA22 for the heart failure community was the results of #STRONGHF. @AlexMebazza, the trial's principal investigator, presented the results. The following thread summarizes his presentation. @AHAScience
#STRONGHF was conducted to determine whether rapid/high-intensity uptitrations of doses of heart failure #GDMT would be safe and effective compared with usual care. @AlexMebazaa @AHAScience #AHA22
Patients received high-intensity care resulting in the successful administration of beta-blockers, RAS inhibitors, & mineralocorticoid receptor antagonists w/in 6 weeks. The primary outcome was hospitalization for HF or all-cause mortality w/in 180 days. @AlexMebazaa #AHA22
#AHA22 LBCTs one liners:
1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.
2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.
1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.
2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.
3. PROMINENT: Pemafibrate did not improve cardiovascular outcomes among patients with diabetes and hypertriglyceridemia.
4. IRONMAN: Iron (ferric derisomaltose) infusion is not superior to usual care among patients with HF and iron deficiency.
4. IRONMAN: Iron (ferric derisomaltose) infusion is not superior to usual care among patients with HF and iron deficiency.
5. EMPA KIDNEY: Empagliflozin has salutary effects on renal function and CV mortality among patients with CKD, with or without DM, who are already on appropriate doses of ACEi/ARB.
🚨🚨📢📢 1/ Beyond thrilled to have our article published in @JACCJournals: “Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials”
jacc.org/doi/10.1016/j.…
Key findings highlighted ⬇️
jacc.org/doi/10.1016/j.…
Key findings highlighted ⬇️
#aha22 - SPORT trial
💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers?
jacc.org/doi/abs/10.101…
@kewatson @ErinMichos @ljlaffin 1/
💊nutraceuticals ubiquitous and “assumed” by many pts to be heart healthy.
💊💰💸industry
💊 SPORT ➡️ compared to rosuva and placebo, do they impact biomarkers?
jacc.org/doi/abs/10.101…
@kewatson @ErinMichos @ljlaffin 1/
N=199, randomized single blind
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo
#aha22 2/
💊 lipid, hsCRP, CMP. Baseline and at 28 days.
💊 1° risk, age 40-75, LDL-C 70-189, borderline to upper intermediate risk (5-20%, estimated 10 yr event)
💊 1° endpt: %LDL-C change vs rosuva
💊2° endpt: biomarkers vs rosuva; vs placebo
#aha22 2/
💊 most were at least 7.5% 10 year risk
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
#aha22 3/
💊 nice representation of 💃🏽
💊 LDL-C >100 (~125); hsCRP <2.0
#aha22 3/
@mmillermd1 @PennCardiology @DLBHATTMD @UM_Cardiology @ASPCardio @nationallipid @BudoffMd @Medscape EPA effect on ASCVD in Japanese pts w/chronic CAD and EPA/AA ratios <0.4, on statins.
🐟EPA 1.8 gm (like JELIS)
🐟EPA baseline 46 ug/mL (JELIS, 96)
🐟All on statins, randomized to control or EPA, no blinding (like JELIS)
#aha22 1/ @AHAScience
🐟EPA 1.8 gm (like JELIS)
🐟EPA baseline 46 ug/mL (JELIS, 96)
🐟All on statins, randomized to control or EPA, no blinding (like JELIS)
#aha22 1/ @AHAScience
@mmillermd1 @PennCardiology @DLBHATTMD @UM_Cardiology @ASPCardio @nationallipid @BudoffMd @Medscape @AHAScience N=2506
🐟interesting drop out rate/protocol deviation, covid era?
🐟LDL-C baseline, similar to reduce it
🐟EPA median 46 ug/mL, higher than reduce it (26), lower than Jelis (96).
🐟hsCRP ~0.40
2/ #aha22
🐟interesting drop out rate/protocol deviation, covid era?
🐟LDL-C baseline, similar to reduce it
🐟EPA median 46 ug/mL, higher than reduce it (26), lower than Jelis (96).
🐟hsCRP ~0.40
2/ #aha22
@mmillermd1 @PennCardiology @DLBHATTMD @UM_Cardiology @ASPCardio @nationallipid @BudoffMd @Medscape @AHAScience 1,800 mg EPA
🐟46 ➡️ 145 ug/mL (26➡️150 ug/mL, reduce it)
🐟LDL-C, Trigs, HDL-C no change
🐟hsCRP went down in both
3/ #aha22
🐟46 ➡️ 145 ug/mL (26➡️150 ug/mL, reduce it)
🐟LDL-C, Trigs, HDL-C no change
🐟hsCRP went down in both
3/ #aha22
Dr @ljlaffin presents the results of the #SPORT trial. Rosuva 5mg/d lowered LDL significantly more than 6 dietary supplements commonly used for cholesterol health. In fact no supplement lowered LDL-C more that placebo and garlic supplement actually raised LDL. #AHA22 @AHAScience
Notably in this short term trial, no increase in musculoskeletal or neurological symptoms or worsening glycemia with rosuva 5. All participants with rosuva 5 had LDL lowering (coin toss for supplements), 50% had LDL>40% reduced with rosuva 5. #AHA22
77% of US adults take supplements and $50 billion is spent annually in US on supplements. But do they lower LDL? These supplements advertise that they help heart health but no better in lowering LDL than placebo not even red yeast rice. @ljlaffin #AHA22 @AHAScience
#AHA22. DESTACADOS DÍA 1⃣📚.
🧵Seguilo hasta el final.
⛔️DCP trial:
💊Clortalidona vs Hidroclorotiazida.
👥13K hipertensos a 2.5 años.
🏁Resultados: ⛔️sin diferencias significativas en pto final combinado (muerte, IAM, IC stroke, revascularización, muerte -no por cáncer-).
🧵Seguilo hasta el final.
⛔️DCP trial:
💊Clortalidona vs Hidroclorotiazida.
👥13K hipertensos a 2.5 años.
🏁Resultados: ⛔️sin diferencias significativas en pto final combinado (muerte, IAM, IC stroke, revascularización, muerte -no por cáncer-).
⛔️TRANSFORM-HF:
💊Torsemida vs Furosemida vía oral en #HF
👥2.8 k 🏥con IC descompensada aleatorizados a furosemida vs torsemida después del alta.
🗓️Seguimiento medio 17 meses.
🏁Resultados: ⛔️sin diferencias en mortalidad por todas las causas u hospitalizaciones🏥.
💊Torsemida vs Furosemida vía oral en #HF
👥2.8 k 🏥con IC descompensada aleatorizados a furosemida vs torsemida después del alta.
🗓️Seguimiento medio 17 meses.
🏁Resultados: ⛔️sin diferencias en mortalidad por todas las causas u hospitalizaciones🏥.
⛔️IRONMAN.
👥1.1K. Fe derisomaltose IV vs plcbo en #HFrEF.
📋Inclusión: FEVI ≤45%, NYHA II–IV, sat. d transferrina <20% o ferritina <100 μg/L, reciente🏥x IC y NTBNP >250 (RS)/> 1000 (FA)
🏁Resultados:⛔️sin diferencias significativas en pto final de muerte CV y🏥por IC.
👥1.1K. Fe derisomaltose IV vs plcbo en #HFrEF.
📋Inclusión: FEVI ≤45%, NYHA II–IV, sat. d transferrina <20% o ferritina <100 μg/L, reciente🏥x IC y NTBNP >250 (RS)/> 1000 (FA)
🏁Resultados:⛔️sin diferencias significativas en pto final de muerte CV y🏥por IC.
Throwing dollars at “health”doesn’t = improved health. This is staggering. We need to change what and how we deliver #Healthcare and where the $$ are spent #aha22
I have never claimed to be fashionable and rarely do I ever match ☺️
I am wearing my heart shoes and my red dress tie from @HeartNews @AHAScience @GoRedForWomen
#AHA22 Day 1
I am wearing my heart shoes and my red dress tie from @HeartNews @AHAScience @GoRedForWomen
#AHA22 Day 1
My shoe buddy and frankly the genesis for why I purchased these shoes @KnightSNPs
Stop by S3156. Dr Knights poster on #disparities in #research. #aha22
We need to fix it.
Stop by S3156. Dr Knights poster on #disparities in #research. #aha22
We need to fix it.
Also, don’t miss Dr Horne’s poster on #statin and #etoh. S3063
If transaminases are elevated and statins are indicated: keep the statin, abstain from etoh
@Intermountain @KirkKnowlton
#aha22
If transaminases are elevated and statins are indicated: keep the statin, abstain from etoh
@Intermountain @KirkKnowlton
#aha22
TRANSFORM-HF
What do we really know about efficacy of furosemide vs torsemide?
I am sure @robmentz and team have something to say about this 👊🏾
pubmed.ncbi.nlm.nih.gov/33714745/
#AHA #LBCT @AHAScience @noshreza
What do we really know about efficacy of furosemide vs torsemide?
I am sure @robmentz and team have something to say about this 👊🏾
pubmed.ncbi.nlm.nih.gov/33714745/
#AHA #LBCT @AHAScience @noshreza
Chlorthalidone versus HCTZ - pragmatic emr study by @Areefishani et al. After #SPRINTTrial I use chlorthalidone. What’s the evidence?
pubmed.ncbi.nlm.nih.gov/35390512/
#AHA #LBCT @AHAScience @noshreza
pubmed.ncbi.nlm.nih.gov/35390512/
#AHA #LBCT @AHAScience @noshreza
PPAR-alpha (e.g., fenofibrate, permafibrate) - Are triglycerides as a target out for CV event reduction, or just this mechanism?
pubmed.ncbi.nlm.nih.gov/30342298/ @APradhanBrigham to present 👊🏾
#AHA #LBCT @AHAScience @noshreza
pubmed.ncbi.nlm.nih.gov/30342298/ @APradhanBrigham to present 👊🏾
#AHA #LBCT @AHAScience @noshreza
Re #aha22 jobs panel. I'm a #twitterstorian working outside of academia- a path I forged w/o help from my alma mater. There's a dearth of helpful advice for ppl being forced out of/choosing to leave academia. Here's what worked for me, what didn't, & what I wish I'd done sooner🧵
Caveats: I'm a cis straight white woman from a middle-class family. My background meant that if absolutely everything fell through, I could've moved back in with my parents (but like I was 29 so omg no thank u)
I started my PhD sure that I wanted to be a prof & would move anywhere to do it. I was told to try the market for 3yrs & if you're open abt location, something will work out. I applied when I was ABD & when I was a postdoc @DolleyPapers, for a total of 20ish jobs over 2 cycles.
As this panel kicks off at #AHA22, I'm struck by the ways in which signifiers like "pizzagate" and "JFK Jr.'s return" have become totally commonplace as to not even prompt raised eyebrows. Like, we have a thing such as "pizzagate" that is, speaking bluntly, bonkers, and...meh, OK
As a historian, I find it so fascinating how quickly these tropes become not just part of the discourse, but so ingrained and normalized as to become banal. The internet is part, but not all, of that story I think.
Very cool that @profrichmond is able to join in via Zoom.
